. Author manuscript; available in PMC: 2021 Nov 23.

Published in final edited form as: Clin Immunol. 2020 Oct 24;221:108616. doi: 10.1016/j.clim.2020.108616

Table 1.

Clinical characteristics of atypical hemolytic uremic syndrome and antiphospholipid antibody syndrome patients

Patient	Diagnosis	Complement Mutations	Age (yr)	Sex	Eculizumab Treatment	Creatinine (mg/dL)		LDH (U/L)		PLT (K/cu mm)		mHam (%)
Patient	Diagnosis	Complement Mutations	Age (yr)	Sex	Eculizumab Treatment	At Diagnosis	Post Ecu	At Diagnosis	Post Ecu	At Diagnosis	Post Ecu	mHam (%)
aHUS_CFH	aHUS	CFH1 Gln950His heterozygous, del (CFHR1-CHFR3) homozygous	53	F	yes	1.6	0.9	2505	180	9	327	43.2 ± 0.125
aHUS_none	aHUS	None detected	27	F	yes	6.3	1.2	2820	195	62	251	36.1 ± 0.099
aHUS_CFI	aHUS	CFI Ile416Leu heterozygous, Thr300Ala homozygous	53	F	yes	4.8	On iHD	3459	231	5	N/A	90.3 ± 13.18
APS	APS	Not performed	43	M	no	11.2	N/A	168	N/A	61	N/A	51.7 ± 9.36

LDH Lactate Dehydrogenase, PLT Platelet count, Ecu Eculizumab. iHD intermittent hemodialysis.